Two studies sharpen the biomarker landscape for women’s cancers and reproductive risk. In cervical cancer detection, two small Sudanese pilot studies reported cervical-cancer-associated loss of heterozygosity (LOH) signals in urine, including cases where Pap smears were normal or non-atypical—while also stressing the need for prospective validation. In addition to screening-adjacent signals, new clinical research continued to explore molecular profiling methods using accessible sample types, including ascites-derived material for ovarian cancer diagnosis and genomic mutation detection. For the sector, urine-based assays could be a practical step toward scalable screening in settings where access to high-quality cytology and follow-up is limited, but the current data remain early-stage. The key near-term question is whether these LOH signals maintain specificity and sensitivity in larger cohorts with prospective sampling and standardized follow-up pathways.